TRVI vs. AMRX, MIRM, OGN, BHC, XENE, GMTX, IBRX, TWST, ARWR, and APLS
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Organon & Co. (OGN), Bausch Health Cos (BHC), Xenon Pharmaceuticals (XENE), Gemini Therapeutics (GMTX), ImmunityBio (IBRX), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.
Trevi Therapeutics vs. Its Competitors
Trevi Therapeutics (NASDAQ:TRVI) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.
95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Trevi Therapeutics had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 4 mentions for Trevi Therapeutics and 3 mentions for Amneal Pharmaceuticals. Trevi Therapeutics' average media sentiment score of 0.95 beat Amneal Pharmaceuticals' score of 0.71 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Trevi Therapeutics presently has a consensus target price of $20.88, indicating a potential upside of 218.70%. Amneal Pharmaceuticals has a consensus target price of $11.60, indicating a potential upside of 39.26%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than Amneal Pharmaceuticals.
Trevi Therapeutics has a net margin of 0.00% compared to Amneal Pharmaceuticals' net margin of -0.46%. Trevi Therapeutics' return on equity of -58.41% beat Amneal Pharmaceuticals' return on equity.
Trevi Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
Trevi Therapeutics has higher earnings, but lower revenue than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Trevi Therapeutics beats Amneal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TRVI) was last updated on 7/11/2025 by MarketBeat.com Staff
